Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced the grant of inducement equity awards to four newly hired non-executive employees as a material inducement to commencing their employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Covered in this story
Call it yourself
No calls on $CABA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Cabaletta Bio →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.